ERYTECH s’introduit avec succès sur NYSE Euronext à Paris

Lyon/Paris, 7 May 2013 – ERYTECH, a Lyon-based biopharmaceutical company that develops innovative therapies to combat acute leukaemia and other forms of cancer, today celebrated its successful listing on NYSE Euronext in Paris (NYX), raising €17.7 million – more than the figure initially targeted by the company.

ERYTECH was founded in 2004 to develop and introduce innovative therapies to fight acute leukaemia and other cancers, addressing medical needs for which current treatments are not suitable. The company's flagship product GRASPA® is currently being developed to treat acute lymphoblastic and myeloid leukaemia in Europe, and is part of a strategic partnership with Recordati-Orphan Europe that covers 38 European countries. GRASPA® also has major potential in the United States and for other indications such as solid tumours.

ERYTECH (ticker code: ERYP) was listed through the admission to trading of 4,015,618 existing shares and 1,524,334 new shares issued under a Global Offering[1]. Given strong demand, the company opted for full exercise of the extension option and partial exercise of the over-allotment option, raising the total to €16.7 million, plus an additional €1 million representing shares subscribed through debt compensation.

The admission and issue price of ERYTECH shares was set at €11.60. Market capitalisation stood at around €64.3 million on the day of listing.

“We would like to extend a warm welcome to ERYTECH – our first listing on this scale from the Rhône-Alpes region, and on the French stock market since the beginning of the year,” said Marc Lefèvre, Head of European Business Development and Client Coverage, Listings Europe, at NYSE Euronext. “By raising €17.7 million – more than the amount initially targeted by the company – it was clearly a success. ERYTECH's listing testifies to renewed interest in the market by both institutional and individual investors.”

Gil Beyen, Chairman and CEO of ERYTECH, commented: “Our successful listing in compartment C of NYSE Euronext in Paris marks a new and important stage in our business development. It brings us both the financial resources and higher profile we need to accelerate our expansion in Europe and the United States, as well as in new cancer indications."

Information:

NYSE Euronext
Caroline Tourrier: +33 (0)1 49 27 10 82 - ctourrier@euronext.com

ERYTECH/ NewCap.
Julien Perez / Emmanuel Huynh: +33 (0)1 44 71 98 52- erytech@newcap.fr

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_Disclaimer
_{This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at}_{www.euronext.com/terms-use}_.